Sterna Biologicals to Participate in Upcoming International Conferences in H1 2018

February 1, 2018 |

2 min read

sterna today announces its participation in the following key scientific and partnering conferences in the first half of 2018.

Marburg, Germany, 01 February 2018 - sterna biologicals GmbH & Co. KG (sterna), an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases, today announces its participation in the following key scientific and partnering conferences in the first half of 2018:

13^th Congress of ECCO - European Crohn's and Colitis Organisation
Date: February 14-17, 2018 in Vienna, Austria

17^th European Dermatology Congress
Date: March 01-03, 2018 in Paris, France

AAAAI/WAO Joint Congress - American Academy of Allergy, Asthma & Immunology and World Allergy Organisation
Date: March 02-05, 2018 in Orlando, USA

BIO-Europe Spring
Date: March 12-14, 2018 in Amsterdam, The Netherlands

German Respiratory Society - 59^th Annual Meeting
Date: March 14-17, 2018 in Dresden, Germany

12^th Global Gastroenterologists Meeting
Date: March 15-16, 2018 in Barcelona, Spain

10th Georg Rajka International Symposium on Atopic Dermatitis (ISAD)
Date: April 11-13, 2018 in Utrecht, The Netherlands

International Investigative Dermatology
Date: May 16-19, 2018 in Orlando, USA

ATS 2018 - American Thoracic Society
Date: May 18-23, 2018 in San Diego, USA

EAACI Congress 2018 - European Academy of Allergy and Clinical Immunology
Date: May 26-30, 2018 in Munich, Germany

2018 BIO International Convention
Date: June 04-07, 2018 in Boston, USA

67^th Annual Meeting of Japanese Society of Allergology 2018
Date: June 22-24, 2018 in Chiba, Japan

World Congress on Gastroenterology and Hepatology
Date: June 25-27, 2018 in Stockholm, Sweden

As further details on the conferences and presentations are available, this information will be updated on the Company's website: http://www.sterna-biologicals.com/. Parties interested in meeting the sterna representatives at one of these conferences, please contact Derya Akar at derya.akar@sterna-biologicals.com.

ABOUT STERNA BIOLOGICALS

Sterna biologicals GmbH & Co. KG is an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases such as asthma, chronic obstructive pulmonary disease (COPD), atopic dermatitis, and ulcerative colitis. By targeting transcription factors that play a pivotal role in regulating Th1 and Th2 inflammatory mechanisms, the Company's proprietary DNAzyme-based drug candidates can intervene with upstream inflammatory processes and address related diseases more effectively. Sterna has currently four programs in Phase II development.

For more information, please visit www.sterna-biologicals.com.

CONTACT

Christian Pangratz
Chief Executive Officer
c.pangratz@sterna-biologicals.com

sterna biologicals GmbH & Co. KG
Bismarckstrasse 7
35037 Marburg
Tel.: +49 (0)6421.98 30 05 0

For media enquiries:

Anne Hennecke
MC Services AG
anne.hennecke@mc-services.eu
Tel.: +49 (0)211.52 92 52 22

Events Europe